Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Why Overstock.com, Zogenix, and Mogu Slumped Today
Monday was a good day on Wall Street, as investors were pleased to see the U.S. take more conciliatory positions on trade issues with major foreign powers. Fears of a global recession are still present, but market participants acknowledge that if news out of Washington gets less confrontational, the odds of avoiding a slowdown should go up. However, some individual companies faced challenges that sent their share prices lower. **Overstock.com **(OSTK 2.71%), **Zogenix **(ZGNX +0.00%), and **Mogu **(MOGU +6.20%) were among the worst performers. Here’s why they did so poorly.
Overstock keeps giving up ground
Shares of Overstock.com continued their downward trend from last week, falling another 16%. Last week’s move was prompted largely by the departure of founder and CEO Patrick Byrne, who left his leadership roles at the company after making controversial statements about his involvement in various political investigations. This morning, interim CEO Jonathan Johnson gave his view on the company’s future, which still appears to be focused on making a transition toward cryptocurrency. Investors don’t seem as comfortable about abandoning Overstock’s original e-commerce business, and that appears to have fueled the stock’s decline today.
Image source: Overstock.com.
Zogenix makes a buy
Drugmaker Zogenix saw its stock drop 16% after it announced an acquisition of a privately held industry peer. Zogenix said that it would pay $250 million to buy Modis Therapeutics, a biotech company that specializes in developing novel therapies for rare genetic diseases. Modis has a late-stage candidate treatment called MT1621 that’s aimed at patients suffering from thymidine kinase 2 deficiency, and it’s gotten FDA breakthrough therapy status. Yet not everyone thinks that Zogenix should have paid as much as it did for Modis, even though one of Zogenix’s own treatment candidates has run into resistance from the U.S. Food and Drug Administration in recent months.
Mogu disappoints
Finally, shares of Mogu plunged 21%. The Chinese online fashion company saw gross merchandise value rise just 2.6% year over year in its fiscal first quarter, and total revenue was down almost 3% over the same period. Mogu did manage to narrow its net losses from the prior-year quarter, but the online retailer is still seeing a significant amount of red ink. There’s plenty of competition in online retail in China, and the company faces a big hurdle to gain market share in a crowded space. Mogu just went public at the end of 2018, but its stock has plunged from its IPO levels, and investors seem to be running out of patience.